Envestnet Asset Management Inc. raised its position in shares of Inogen, Inc. (NASDAQ:INGN – Get Rating) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,160 shares of the medical technology company’s stock after acquiring an additional 5,306 shares during the period. Envestnet Asset Management Inc. owned approximately 0.23% of Inogen worth $1,028,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Oppenheimer Asset Management Inc. lifted its stake in Inogen by 23.6% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 15,709 shares of the medical technology company’s stock worth $310,000 after purchasing an additional 2,999 shares during the last quarter. Mission Wealth Management LP grew its position in Inogen by 113.8% in the 4th quarter. Mission Wealth Management LP now owns 76,635 shares of the medical technology company’s stock valued at $1,510,000 after acquiring an additional 40,795 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Inogen by 31.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,230 shares of the medical technology company’s stock valued at $64,000 after acquiring an additional 764 shares during the last quarter. Versor Investments LP grew its position in Inogen by 97.8% in the 4th quarter. Versor Investments LP now owns 18,200 shares of the medical technology company’s stock valued at $359,000 after acquiring an additional 9,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Inogen by 171.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 70,559 shares of the medical technology company’s stock valued at $1,391,000 after acquiring an additional 44,576 shares during the last quarter. Institutional investors own 95.93% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on INGN shares. StockNews.com lowered shares of Inogen from a “hold” rating to a “sell” rating in a report on Friday, May 12th. Needham & Company LLC reissued a “buy” rating and issued a $26.00 price objective on shares of Inogen in a research note on Thursday, April 20th.
Inogen Stock Performance
Inogen (NASDAQ:INGN – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The medical technology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.14. Inogen had a negative net margin of 24.36% and a negative return on equity of 11.06%. The business had revenue of $72.16 million for the quarter, compared to analysts’ expectations of $74.68 million. During the same period last year, the business earned ($0.38) EPS. The company’s revenue was down 10.2% compared to the same quarter last year. On average, analysts forecast that Inogen, Inc. will post -2.16 earnings per share for the current fiscal year.
Inogen, Inc is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.
- Get a free copy of the StockNews.com research report on Inogen (INGN)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.